Funding Support and Author Disclosures Dr Chirinos is supported by National Institutes of Health grants R01-HL 121510, U01-TR003734, 3U01TR003734-01W1, U01-HL160277, R33-HL-146390, R01-HL153646, K24-AG070459, R01-AG058969, R01-HL104106, P01-HL094307, R03-HL146874, R56-HL136730, R01 HL155599, R01 HL157264, R01HL155, and 1R01HL153646-01. Dr Chirnos has served as a consultant for Bayer, Sanifit, Fukuda-Denshi, Bristol-Myers Squibb, Johnson & Johnson, Edwards Life Sciences, Merck, NGM Biopharmaceuticals and the Galway-Mayo Institute of Technology; has received research grants to the University of Pennsylvania from National Institutes of Health, Fukuda-Denshi, Bristol-Myers Squibb, Microsoft, and Abbott; has been named as inventor in a University of Pennsylvania patent for the use of inorganic nitrates/nitrites for the treatment of heart failure and on a patent application for the use of a novel biomarker (endotrophin) in heart failure with preserved ejection fraction; has received payments for editorial roles from the American Heart Association, the American College of Cardiology, and Wiley; and has received research device loans from Atcor Medical, Fukuda-Denshi, Uscom, NDD Medical Technologies, Microsoft, and MicroVision Medical.